| 货号 | 16022-25mg |
| 描述 | Tamoxifen (TMX; Item No. 13258) is a selective estrogen receptor (ER) modulator used as adjuvant therapy for estrogen-dependent breast cancer.1 Endoxifen is an active metabolite of TMX, produced by the sequential action of cytochrome P450 (CYP) isoforms, including CYP2D6.2,3,4 It is a strong anti-estrogen, as it has an approximately 100-fold greater affinity for ERs than TMX.2 As the efficient conversion of TMX to endoxifen depends on CYP2D6, polymorphisms in this CYP isoform can impact the effectiveness of TMX treatment.2,3,4 |
| 别名 | N-Desmethyl-4-Hydroxytamoxifen;4-Hydroxy-N-Desmethyltamoxifen; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Clarke, M.,Collins, R.,Davies, C., et al. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351, 1451-1467 (1998). 2.Brauch, H.,Mürdter, T.E.,Eichelbaum, M., et al. Pharmacogenomics of tamoxifen therapy. Clin. Chem. 55(10), 1770-1782 (2009). 3.Mugundu, G.M.,Sallans, L.,Guo, Y., et al. Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes. Drug Metabolism and Disposition 40(2), 389-396 (2012). 4.Markopoulos, C.,Kykalos, S. and Mantas, D. Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen. World J. Clin. Oncol. 5(3), 374-381 (2014). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 373.5 |
| 分子式 | C25H27NO2 |
| CAS号 | 112093-28-4 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |